Lipocine announces fda affirmation of class 1 nda resubmission for tlando®

Salt lake city, sept. 28, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the u.s. food and drug administration ("fda") has affirmed the resubmission of its new drug application ("nda") for tlando®, its oral testosterone product, will be a class 1 resubmission.
LPCN Ratings Summary
LPCN Quant Ranking